An anticipated Phase III trial of Riquent in lupus, meant to confirm data trends seen in a Phase II/III trial, brought about a similar result - good data trends but a missed primary endpoint, sending La Jolla Pharmaceutical Co.'s stock down 72.5 percent. (BioWorld Today) Read More
